| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
Lirilumab manufacturers
- Lirilumab
-
- $183.00
-
2026-07-22
- CAS:1000676-41-4
- Purity: 95.00%
- Supply Ability: 10g
|
| | Lirilumab Basic information |
| Product Name: | Lirilumab | | Synonyms: | Lirilumab;Research Grade Lirilumab(DHE43401);ONO-4483|||IPH2102;Research Grade Lirilumab;Lirilumab (anti-KIR) | | CAS: | 1000676-41-4 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Lirilumab Structure]() |
| | Lirilumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Lirilumab Usage And Synthesis |
| Uses | Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research[1][2]. | | in vivo | Lirilumab (intravenous injection; 15 mg/kg; once) treatment enhances survival rate of mice injected with tumor[2]. | Animal Model: | Rag1KO-Tg KIR mice injected with tumor cells[2] | | Dosage: | 15 mg/kg | | Administration: | intravenous injection; 15 mg/kg; once | | Result: | Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died. |
| | References | [1] Hanna GJ, et al. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Feb 1;28(3):468-478. DOI:10.1158/1078-0432.CCR-21-2635
[2] Kohrt HE, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 2014 Jan 30;123(5):678-86. DOI:10.1182/blood-2013-08-519199 |
| | Lirilumab Preparation Products And Raw materials |
|